Fig. 4From: Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patientsImprovement in PEF (L/min) with indacaterol maleate and indacaterol acetate versus placebo at Day 14. Data are presented as LS mean treatment difference (95% CI). LS, least square; N, No. of patients; PEF, peak expiratory flowBack to article page